Volume 11, Number 6—June 2005
Dispatch
Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–20031
Surbhi Malhotra-Kumar*
, Christine Lammens*, Sabine Chapelle*, Monique Wijdooghe*, Jasper Piessens*, Koen Van Herck*, and Herman Goossens*
, Christine Lammens*, Sabine Chapelle*, Monique Wijdooghe*, Jasper Piessens*, Koen Van Herck*, and Herman Goossens*Table A2
Temporal changes in pulsed-field gel electrophoresis (PFGE) and emm type distribution among 3 macrolide-resistant Streptococcus pyogenes phenotypes
| Macrolide-resistant phenotype | Emm type | PFGE cluster* | Frequency (n=506) | No. (%) of macrolide-resistant S. pyogenes |
||||
|---|---|---|---|---|---|---|---|---|
| 1999 (n=81) | 2000 (n=41) | 2001 (n=73) | 2002 (n=215) | 2003 (n=96) | ||||
| cMLS | emm22 | 1 | 70 | 45 (56) | 7 (17) | 9 (12) | 7 (3) | 2 (2) |
| 1057 | 1 | 1 (0.4) | ||||||
| emm4 | 10 | 9 | 9 (12) | |||||
| 11 | 8 | 3 (4) | 2 (3) | 2 (1) | 1 (1) | |||
| 1002 | 1 | 1 (1) | ||||||
| 1009 | 2 | 2 (5) | ||||||
| emm76 | 32 | 1 | 1 (1) | |||||
| emm2 | new2 | 1 | 1 (2) | |||||
| emm28 | 4 | 45 | 4 (5) | 15 (7) | 26 (27) | |||
| emm11 | 23 | 28 | 1 (1) | 6 (3) | 21 (22) | |||
| emm75 | 15 | 1 | 1 (1) | |||||
| emm6 | 5 | 1 | 1 (1) | |||||
| emm12 | 6 | 1 | 1 (1) | |||||
| 57 | 11 | 8 (4) | 3 (3) | |||||
| emm77 | 10 | 6 | 6 (3) | |||||
| NT† | 2 | 3 | 3 (1) | |||||
| 49 | 12 | 12 (6) | ||||||
| 64 | 4 | 4 (2) | ||||||
| 65 | 1 | 1 (0.4) | ||||||
| 69 | 2 | 2 (1) | ||||||
| 70 | 1 | 1 (0.4) | ||||||
| M | emm1 | 1001 | 128 | 7 (9) | 12 (29) | 23 (32) | 80 (37) | 6 (6) |
| 1022 | 2 | 2 (2) | ||||||
| 3 | 1 | 1 (1) | ||||||
| emm12 | 6 | 1 | 1 (0.4) | |||||
| 1011 | 10 | 4 (5) | 2 (5) | 3 (4) | 1 (0.4) | |||
| 1025 | 10 | 3 (4) | 2 (1) | 5 (5) | ||||
| 1026 | 2 | 2 (2) | ||||||
| 1027 | 1 | 1 (1) | ||||||
| 1030 | 2 | 1 (2) | 1 (0.4) | |||||
| 1035 | 9 | 1 (1) | 4 (2) | 4 (4) | ||||
| 1044 | 1 | 1 (0.4) | ||||||
| 1047 | 2 | 2 (1) | ||||||
| emm2 | 18 | 1 | 1 (1) | |||||
| 1038 | 1 | 1 (1) | ||||||
| new 3 | 1 | 1(1) | ||||||
| 1042 | 1 | 1 (0.4) | ||||||
| 1034 | 1 | 1 (1) | ||||||
| 1049 | 1 | 1 (0.4) | ||||||
| emm4 | 1002 | 28 | 2 (2.5) | 2 (5) | 7 (10) | 7 (3) | 10 (10) | |
| 1007 | 2 | 2 (5) | ||||||
| 1008 | 1 | 1 (1) | ||||||
| 1009 | 1 | 1 (2) | ||||||
| 1010 | 11 | 1 (1) | 3 (7) | 2 (3) | 2 (1) | 3 (3) | ||
| 1019 | 1 | 1 (1) | ||||||
| 1021 | 2 | 2 (2) | ||||||
| 1043 | 1 | 1 (0.4) | ||||||
| 1044 | 3 | 3 (3) | ||||||
| 1054 | 2 | 2 (1) | ||||||
| 1059 | 1 | 1 (0.4) | ||||||
| emm77 | 1028 | 4 | 4 (10) | |||||
| 9 | 2 | 1 (2) | 1 (1) | |||||
| 10 | 3 | 3 (1) | ||||||
| emm75 | 1036 | 1 | 1 (1) | |||||
| 1060 | 1 | 1 (0.4) | ||||||
| emm33 | 1046 | 2 | 2 (1) | |||||
| 1052 | 2 | 2 (1) | ||||||
| emm78 | 1042 | 1 | 1 (0.4) | |||||
| emm28 | 1033 | 1 | 1 (1) | |||||
| emm9 | 1042 | 2 | 2 (2) | |||||
| emm60 | 8 | 1 | 1 (1) | |||||
| NT | 42 | 1 | 1 (1) | |||||
| 1018 | 1 | 1 (2) | ||||||
| 62 | 3 | 3 (1) | ||||||
| 71 | 1 | 1 (0.4) | ||||||
| 1005 | 2 | 2 (1) | ||||||
| 1012 | 2 | 2 (1) | ||||||
| 1033 | 2 | 2 (1) | ||||||
| 1042 | 1 | 1 (0.4) | ||||||
| 1043 | 3 | 3 (1) | ||||||
| 1044 | 3 | 3 (1) | ||||||
| 1045 | 1 | 1 (0.4) | ||||||
| 1049 | 3 | 3 (1) | ||||||
| 1050 | 1 | 1 (0.4) | ||||||
| 1051 | 1 | 1 (0.4) | ||||||
| 1055 | 1 | 1 (0.4) | ||||||
| 1058 | 1 | 1 (0.4) | ||||||
| 1061 | 2 | 2 (2) | ||||||
| 83 | 1 | 1 (1) | ||||||
| 26 | 1 | 1 (1) | ||||||
| iMLS | emm1 | 1031 | 1 | 1 (2) | ||||
| emm22 | 1 | 2 | 2 (3) | |||||
| emm4 | 10 | 1 | 1 (1) | |||||
| emm9 | 61 | 1 | 1 (1) | |||||
| emm77 | 9 | 2 | 1 (1) | 1 (0.4) | ||||
| 10 | 1 | 1 (0.4) | ||||||
| 50 | 2 | 1 (1) | 1 (0.4) | |||||
| emm12 | 57 | 1 | 1 (0.4) | |||||
| emm18 | 1048 | 1 | 1 (0.4) | |||||
| emm89 | 77 | 1 | 1 (1) | |||||
| NT | new 1 | 1 | 1 (2) | |||||
| 63 | 1 | 1 (0.4) | ||||||
| 49 | 3 | 3 (3) | ||||||
*PFGE profile numbers from 1-100 designate restriction with SmaI and above 1,000 restriction profiles generated with SfiI.
†NT, non-typeable.
1A preliminary account of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington DC, USA.
